Niemann-Pick Disease Type C - cyclotherapeutics
Descrição
The pathogenesis of Niemann–Pick type C disease: a role for autophagy?, Expert Reviews in Molecular Medicine
Niemann-Pick Disease Type C Treatment Market Size & Trends 2020- expected to reach US$ 378.8 Million With CAGR of 42.3% by 2027, Orphazyme A/S, Cyclo Therapeutics, Inc., and Johnson & Johnson
Presentations of Niemann-Pick Type C disease
Niemann–Pick type C disease: cellular pathology and pharmacotherapy - Wheeler - 2020 - Journal of Neurochemistry - Wiley Online Library
NiemannPick: a debilitating disease with fatal outcomes. Learn more about our Phase 3 program for #NPC1 here: Cyclo Therapeutics, Inc. posted on the topic
TransportNPC: Phase 3 Study in Niemann-Pick Disease Type C - cyclotherapeutics
Niemann–Pick type C disease: cellular pathology and pharmacotherapy - Wheeler - 2020 - Journal of Neurochemistry - Wiley Online Library
Niemann-Pick disease type C, Orphanet Journal of Rare Diseases
Cyclodextrin News
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
When to Suspect Niemann-Pick Type C (NPC)
PDF] Niemann-Pick Type C Disease—Pathophysiology and Future Perspectives for Treatment
The Niemann-Pick Type C (NPC) market size was $128.35 million in 2021 and is forecast to achieve a CAGR of more than 3% during the forecast period.
Niemann-Pick Type C Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial
de
por adulto (o preço varia de acordo com o tamanho do grupo)
